Home   Business   Life Science

Subscribe Now

Life Science




Jane Osbourn becomes CEO of Alchemab Therapeutics

Jane Osbourn becomes CEO of Alchemab Therapeutics

Jane Osbourn becomes CEO of Alchemab Therapeutics

Adaptive immunity company heads for next phase.


Additional $12m boosts PhoreMost’s Series B total to $50m for drug pipeline

Additional $12m boosts PhoreMost’s Series B total to $50m for drug pipeline

Additional $12m boosts PhoreMost’s Series B total to $50m for drug pipeline

Novel degrader programmes in oncology and inflammatory diseases head for preclinical development.


Financial show of strength from Bicycle Therapeutics

Financial show of strength from Bicycle Therapeutics

Financial show of strength from Bicycle Therapeutics

Results to 30 June, 2024 reveal a strengthened balance sheet.


Healx’s $47m Series C raise will speed up Healnet’s drug discoveries

Healx’s $47m Series C raise will speed up Healnet’s drug discoveries

Healx’s $47m Series C raise will speed up Healnet’s drug discoveries

First Phase 2 clinical trial as FDA approval sought.


Life sciences networking events organiser Conexen to open in Oxford and London

Life sciences networking events organiser Conexen to open in Oxford and London

Life sciences networking events organiser Conexen to open in Oxford and London

Next Cambridge meet-up is 18 September.


Winners of the 2024 Cambridge Independent Science and Technology Awards revealed

Winners of the 2024 Cambridge Independent Science and Technology Awards revealed

Winners of the 2024 Cambridge Independent Science and Technology Awards revealed

Find out who triumphed in the annual awards, held on the Wellcome Genome Campus.


Pangenomics to enter the quantum era with ‘incredibly exciting’ $3.5m project

Pangenomics to enter the quantum era with ‘incredibly exciting’ $3.5m project

Pangenomics to enter the quantum era with ‘incredibly exciting’ $3.5m project

University of Cambridge, Wellcome Sanger Institute and EMBL-EBI to team up.


AstraZeneca completes equity investment in Cellectis

AstraZeneca completes equity investment in Cellectis

AstraZeneca completes equity investment in Cellectis

It now has a 44 per cent stake in the clinical-stage biotechnology company.


How Nanocage vaccine could provide broad protection against coronaviruses - including ones we don’t know exist yet

How Nanocage vaccine could provide broad protection against coronaviruses - including ones we don’t know exist yet

How Nanocage vaccine could provide broad protection against coronaviruses - including ones we don’t know exist yet

Cambridge, Oxford and Caltech researchers have tested it in mice so far.


Results speak of “bright and profitable future” for Cambridge Cognition

Results speak of “bright and profitable future” for Cambridge Cognition

Results speak of “bright and profitable future” for Cambridge Cognition

Neuroscience technologies to assess cognitive function go global.


ELRIG UK enters into partnership with life science recruitment leaders SRG

ELRIG UK enters into partnership with life science recruitment leaders SRG

ELRIG UK enters into partnership with life science recruitment leaders SRG

Helping to grow the sector with access to career opportunities.


Markus Lusser takes charge at Abcam

Markus Lusser takes charge at Abcam

Markus Lusser takes charge at Abcam

New president is seasoned Danaher executive.


Cellular Highways hits the Highway1 launch button

Cellular Highways hits the Highway1 launch button

Cellular Highways hits the Highway1 launch button

World’s fastest chip-based cell sorting tool now available for installation.


Neobe Therapeutics closes $2.3m round for its cancer disruptor

Neobe Therapeutics closes $2.3m round for its cancer disruptor

Neobe Therapeutics closes $2.3m round for its cancer disruptor

Synthetic biology start-up acts on tumours without affecting healthy tissues.


This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More